EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer

Uri Amit iD, James M Metz, John P Plastaras, Rohi Gheewala, Ursina Teitelbaum, Nevena Damjanov, Charles Vollmer, Charles J Schneider, Major Kenneth Lee, Mark O'Hara, Kim Reiss-Binder, Erica L Carpenter und 4 weitere

Cancer · 2025

DOI: 10.1002/cncr.35936 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, 2025. Verfasst von Uri Amit und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Paclitaxel, Albumins, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This phase 1 dual dose‐escalation study aimed to evaluate the safety, feasibility, and toxicity profile of combining dose‐escalated radiation therapy with high‐dose nab‐paclitaxel in patients with unresectable or borderline resectable pancreatic cancer. Methods and Materials Twenty‐one evaluable patients were enrolled and allocated three radiation dose levels, 55 Gy, 57.5 Gy, and 60 Gy, administered over 5 weeks in 25 fractions. Concurrent nab‐paclitaxel was given weekly at a dose of 125 mg/m 2 . Radiation dose escalation was guided by a time‐to‐event continual reassessment method. Toxicities were classified according to CTCAE v4.0, with dose‐limiting toxicities (DLT) defined as grade 3 or higher gastrointestinal events or substantial decline in performance status. Surgical resection was pursued in patients achieving sufficient tumor downstaging.

Results

Hematologic toxicities were the most common grade ≥3 adverse events occurring in 76.2% of patients. Nonhematologic toxicities were less frequent (57.1%). Two grade 3 gastrointestinal DLT cases occurred at dose levels 57.5 Gy and 60 Gy. The maximum tolerated dose was 60 Gy with a probability of DLT of 0.155 at this dose. Surgical resection with negative margins was achieved in 33.3% of patients, including all borderline resectable cases and 22.2% of initially unresectable cases. The median overall survival and time to local progression from the start of radiation therapy were 22.3 months and 20.3 months, respectively.

Conclusions

This study demonstrates the feasibility and safety of combining dose‐escalated radiation with high‐dose nab‐paclitaxel in locally advanced pancreatic cancer. The regimen is associated with manageable toxicity and promising local control and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsPaclitaxelAlbuminsChemoradiotherapyHumansMaleFemaleAgedMiddle AgedAdultMaximum Tolerated DoseFeasibility StudiesTreatment Outcome

Stichwörter der Autor:innen

dose escalationnab‐paclitaxelpancreatic cancerradiation therapy

Substanzen

130-nm albumin-bound paclitaxelPaclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Department of Radiation Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Uri Amit

Förderung

  • University of Pennsylvania

Zitieren

APA

Amit, U., Metz, J. M., Plastaras, J. P., Gheewala, R., Teitelbaum, U., Damjanov, N., Vollmer, C., Schneider, C. J., Lee, M. K., O'Hara, M., Reiss-Binder, K., Carpenter, E. L., Karasic, T. B., Konski, A., Wileyto, E. P., & Ben-Josef, E. (2025). A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Cancer. https://doi.org/10.1002/cncr.35936

Vancouver

Amit U, Metz JM, Plastaras JP, Gheewala R, Teitelbaum U, Damjanov N, et al. A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Cancer. 2025. doi:10.1002/cncr.35936

BibTeX
@article{Amit2025,
  author = {Amit, Uri and Metz, James M and Plastaras, John P and Gheewala, Rohi and Teitelbaum, Ursina and Damjanov, Nevena and Vollmer, Charles and Schneider, Charles J and Lee, Major Kenneth and O'Hara, Mark and Reiss-Binder, Kim and Carpenter, Erica L and Karasic, Thomas B and Konski, Andre and Wileyto, E Paul and Ben-Josef, Edgar},
  title = {A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35936}
}
Kostenlos starten →